The Clinicopathological and Molecular Characteristics of Resected EGFR-mutant Lung Adenocarcinoma

Overview

Journal Cancer Med

Specialty Oncology

Date 2022 Jan 13

PMID 35023616

Authors

Wensheng Zhou

Zhichao Liu

Yanan Wang

Yanwei Zhang

Fangfei Qian

Jun Lu

Huimin Wang

Ping Gu

Minjuan Hu

Ya Chen

Zhengyu Yang

Ruiying Zhao

Yuqing Lou

Baohui Han

Wei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Epidermal growth factor receptor (EGFR) mutations were frequently found with concomitant genetic alterations in lung adenocarcinoma (LUAD). This study aimed to investigate the profile of concomitant alterations of EGFR-mutant LUAD ≤3 cm in size and its prognostic effect on recurrence.

Methods: From January 2018 to December 2018, patients with resected LUAD ≤3 cm in size in Shanghai Chest Hospital were identified. All patients underwent capture-based targeted next-generation sequencing (NGS) with a panel of 68 lung cancer-related genes and were found with EGFR mutation. Clinicopathological and molecular characteristics and recurrence-free survival (RFS) were analyzed.

Results: A total of 637 patients were enrolled in this study. The top three frequent co-mutational genes were TP53 (179 of 637, 28.1%), PIK3CA (27 of 637, 4.2%), and ATM (22 of 637, 3.5%). The most common amplified genes were EGFR (37 of 637, 5.8%), followed by CDK4 (37 of 637, 5.8%) and MYC (12 of 637, 2.0%). Only TP53 mutation and EGFR amplification were adverse prognostic factors for RFS (all p < 0.001) in univariate analysis. Multivariable analysis further demonstrated that TP53 mutation and EGFR amplification were independent risk factors for RFS [(hazard ratio (HR) 2.07, 95% confidence interval (CI) 1.07-4.00, p = 0.030; HR 3.09, 95% CI 1.49-6.40, p = 0.002, respectively].

Conclusions: Concomitant TP53 mutation and EGFR amplification were poor prognostic factors for RFS in patients with EGFR-mutant resected LUAD. Our findings provide valuable understanding of the impact of concurrent alterations and implication for better implementation of precision therapy for patients.

Citing Articles

EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer.

Goffinet S, Bontoux C, Heeke S, Pezzuto F, Ilie M, Long-Mira E Virchows Arch. 2024; .

PMID: 39741211 DOI: 10.1007/s00428-024-04010-4.

TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases.

Lin T, Tang X, Yang W, Yang H, Zhou Z, Chen Z Heliyon. 2024; 10(16):e36532.

PMID: 39258211 PMC: 11385771. DOI: 10.1016/j.heliyon.2024.e36532.

Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis.

Zhou C, Jing Z, Liu W, Ma Z, Liu S, Fang Y Sci Rep. 2023; 13(1):18710.

PMID: 37907475 PMC: 10618289. DOI: 10.1038/s41598-023-42851-2.

A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer.

Cao W, Tang Q, Zeng J, Jin X, Zu L, Xu S Cancers (Basel). 2023; 15(18).

PMID: 37760531 PMC: 10526902. DOI: 10.3390/cancers15184561.

Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.

Lee J, McNamee C, Toloza E, Negrao M, Lin J, Shum E J Thorac Oncol. 2023; 18(11):1458-1477.

PMID: 37451404 PMC: 11040203. DOI: 10.1016/j.jtho.2023.07.006.

References

Gerstung M, Jolly C, Leshchiner I, Dentro S, Gonzalez S, Rosebrock D . The evolutionary history of 2,658 cancers. Nature. 2020; 578(7793):122-128. PMC: 7054212. DOI: 10.1038/s41586-019-1907-7. View

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

Chen J, Yang H, Teo A, Amer L, Sherbaf F, Tan C . Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020; 52(2):177-186. DOI: 10.1038/s41588-019-0569-6. View

Takamochi K, Oh S, Matsunaga T, Suzuki K . Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2017; 154(5):1768-1774.e1. DOI: 10.1016/j.jtcvs.2017.06.062. View

Passaro A, Janne P, Mok T, Peters S . Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2022; 2(4):377-391. DOI: 10.1038/s43018-021-00195-8. View

Zhong W, Wang Q, Mao W, Xu S, Wu L, Wei Y . Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2020; 39(7):713-722. PMC: 8078324. DOI: 10.1200/JCO.20.01820. View

Ozaki Y, Muto S, Takagi H, Watanabe M, Inoue T, Fukuhara M . Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer. Cancer Immunol Immunother. 2019; 69(1):127-134. PMC: 11027844. DOI: 10.1007/s00262-019-02446-1. View

Zhang T, Joubert P, Ansari-Pour N, Zhao W, Hoang P, Lokanga R . Genomic and evolutionary classification of lung cancer in never smokers. Nat Genet. 2021; 53(9):1348-1359. PMC: 8432745. DOI: 10.1038/s41588-021-00920-0. View

Martincorena I, Campbell P . Somatic mutation in cancer and normal cells. Science. 2015; 349(6255):1483-9. DOI: 10.1126/science.aab4082. View

10.

Levine A . p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020; 20(8):471-480. DOI: 10.1038/s41568-020-0262-1. View

11.

Kim Y, Lee B, Shim J, Lee S, Park W, Choi Y . Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. J Thorac Oncol. 2018; 14(2):193-202. DOI: 10.1016/j.jtho.2018.10.150. View

12.

Fukuoka M, Wu Y, Thongprasert S, Sunpaweravong P, Leong S, Sriuranpong V . Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29(21):2866-74. DOI: 10.1200/JCO.2010.33.4235. View

13.

Ma X, Le Teuff G, Lacas B, Tsao M, Graziano S, Pignon J . Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. J Thorac Oncol. 2016; 11(6):850-61. DOI: 10.1016/j.jtho.2016.02.002. View

14.

Kim T, Song A, Kim D, Kim S, Ahn Y, Keam B . Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor. J Thorac Oncol. 2015; 10(12):1736-44. DOI: 10.1097/JTO.0000000000000688. View

15.

Deng C, Zhang Y, Ma Z, Fu F, Deng L, Li Y . Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2020; 162(3):664-674.e7. DOI: 10.1016/j.jtcvs.2020.05.099. View

16.

Jamal-Hanjani M, Wilson G, McGranahan N, Birkbak N, Watkins T, Veeriah S . Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(22):2109-2121. DOI: 10.1056/NEJMoa1616288. View

17.

Shan L, Wang Z, Guo L, Sun H, Qiu T, Ling Y . Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients. Lung Cancer. 2015; 89(3):337-42. DOI: 10.1016/j.lungcan.2015.06.008. View

18.

Deng Q, Qiu Y, Jia J, Tang H, Liu L, Huang L . Genetic alteration profile of -mutant resected IIB-IIIA stage NSCLC and correlation to clinical outcomes. Transl Lung Cancer Res. 2020; 8(6):838-846. PMC: 6976375. DOI: 10.21037/tlcr.2019.10.19. View

19.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

20.

Hong S, Gao F, Fu S, Wang Y, Fang W, Huang Y . Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(5):739-742. PMC: 5885210. DOI: 10.1001/jamaoncol.2018.0049. View